LSI

The ABCs of LSI USA ‘25 — Today’s letter of the day is B for “Building a Winning Board — Hits and Misses” A strong board can be a startup’s greatest asset or its biggest challenge. This workshop unpacked the key traits of an effective board, common missteps to avoid, and how to build the right mix of expertise and leadership to drive success. This workshop featured: ? Nick Pachuda — Innovation & New Ventures, Precision Life Science Partners ? Tamir Meiri — Director, Venture Investments, Johnson & Johnson MedTech ? Rui Jing J. — Founder & CEO, Avisi Technologies ? Jeffrey O'Donnell Sr. — Managing General Partner, Runway Healthcare L.P. ? Stefan Fischer — Managing Partner, TVM Capital Life Science The video recordings of this workshop will be available in the coming weeks. Tune in each day as we recap LSI USA ‘25 from A to Z. PS: Registration is now open for LSI USA ‘26 next March 16-20 in Dana Point, California. Secure your spot early to take advantage of our best rates and have priority for our hotel room block.

What Makes Singapore the Right Place for LSI Asia ‘25? Singapore's rise as a leading startup ecosystem is nothing short of remarkable. It has risen to be on a similar footing as traditional powerhouses like Beijing, backed by a supportive government, prominent institutional investors, sovereign wealth funds, family offices, and high-net-worth individuals, and attractive tax and financial structures that inspire flexible and efficient innovation and investment activity. Singapore's Medtech sector is particularly noteworthy. The country's commitment to fostering a conducive environment for medical device development, innovation, and manufacturing is evident by its outsized production of locally-made medical devices that punch above their weight on the global stage. The synergy between public policy, private enterprise, and academic research has created a positive feedback loop to nurture startups and attract capital at scale. Often referred to as a “gateway” to Southeast Asia, Singapore's strategic location makes it an ideal hub for connecting executives across Asia with one another, and with our established global community built through our parallel events in the USA and Europe. And of course, in selecting a location, it is paramount that we stay true to our ethos and find a world-class venue where senior executives can do real business. The Ritz-Carlton, Millenia Singapore is an award-winning, five-star property with authentic Cantonese Michelin-star restaurants, panoramic views, spacious accommodations, and state-of-the-art meeting and AV facilities. We’re confident our guests won’t mind stopping by Republic Bar either, which ranks among one of Asia's 50 Best Bars. Read the full article, “From Our CEO: Going Global With LSI Asia’s Launch in Singapore,” for the full story: https://lnkd.in/gmshyzFj Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are open. Secure your spot today to join us at LSI Asia ‘25 on June 10th-13th at The Ritz-Carlton, Millenia Singapore.

The ABCs of LSI USA ‘25 — Today’s letter of the day is B for Build to Buy. These sessions took a hard look at the build-to-buy model—examining what it means to grow a company with acquisition as the endgame. Speakers shared insights on timing, alignment, and deal dynamics, while also confronting the realities of shifting market conditions, changing strategic priorities, and the risks that can derail even the best-laid plans. New Era — Build to Buys ? Joe Mullings — Chairman & CEO, The Mullings Group ? Ramin Mousavi — President, CEO & Board Director, CathWorks ? Andrew ElBardissi, MD — Partner, Deerfield Management ? Addie H. — 1955 Capital ? Josh Makower — Stanford Mussallem Center for Biodesign Runaway Brides: Build-to-Buys at the Altar of Consummation (a Guide to Reinsurance Dating) ? Christopher Cleary — CEO, Biomergence Capital ? Hanson Gifford — Managing Partner, The Foundry and Partner, Lightstone Ventures ? Andrew Cleeland — CEO, Fogarty Innovation Signature Series: To Build or To Buy? Stryker's Thesis for AI, Robotics, and Organic vs Inorganic Growth ? Spencer Stiles, Group President, Orthopaedics and Spine at Stryker ? Moderated by Emily West, Managing Director at Goldman Sachs The video recordings of these sessions will be available in the coming weeks. Tune in each day as we recap LSI USA ‘25 from A to Z. PS: Registration is now open for LSI USA ‘26 next March 16-20 in Dana Point, California. Secure your spot early to take advantage of our best rates and have first priority for our hotel room block. #LSIUSA25

Biorithm (LSI Asia ‘25 Presenter) has a mission to end preventable pregnancy complications while reshaping how pregnancy care is delivered. The company is developing a comprehensive maternity care platform, Femom, to improve perinatal outcomes. The Femom platform merges clinical-grade fetal monitor data with patient reported symptoms and more traditional biometrics (e.g., glucose, blood pressure) to provide clinicians with new insights into the health of the mother and baby. Biorithm has reached significant milestones, including: ? Raised a $3.5M in Series A1 funding round co-led by Adaptive Capital Partners and SEEDS Capital (December 2023) ? Appointed Jenny Hoffmann, PhD as CEO (July 2024) ? Has four papers published in Tier 1 journals ? Two ongoing home-based studies in the US and UK to demonstrate a new maternity care standard. ? Currently has 600 patients enrolled worldwide To dive deeper into Biorithm’s mission and innovation, watch CEO, Jenny Hoffman’s LSI Europe ‘24 presentation on our website and YouTube channel. You can also connect with Founder Amrish Nair directly at LSI Asia '25 where he’s been selected to present Biorithm. Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are now open. Secure your spot today to join us at LSI Asia ‘25 on June 10th-13th at The Ritz-Carlton, Millenia Singapore.

The decision to launch LSI Asia is a response to the evolving dynamics of the global Medtech industry and our growing global community. Over the past few years, we have witnessed the Asia Pacific region emerge as a hotbed for innovation, capital, manufacturing, and business development. We’ve seen a shift from “me too” plays in the region to globally consequential innovation at the forefront of Deep Tech, Robotics, AI, and more. Chronic diseases like diabetes, cardiovascular diseases, cancers, and diseases of aging are driving policy, necessitating investment, and seeding a vibrant startup ecosystem. LSI’s Market Intelligence team even projects that China will surpass the United States in the total volume of tracked surgical procedures in 2024, with four of the five fastest-growing countries in total volume being in Asia (China, India, South Korea, and Singapore). This region is no longer just an emerging player; it is a critical driver of global Medtech growth. For executives operating outside of Asia, the region represents a "next frontier." Asia is characterized by a rapidly growing ecosystem of medical device startups, significant LP and investment activity, and the presence of major strategic players. This convergence of factors makes it the perfect time to establish a dedicated platform that caters to the unique needs and opportunities in the region, showcases both local and global innovation, and facilitates strategic partnerships domestically and across borders. Read the full article, “From Our CEO: Going Global With LSI Asia’s Launch in Singapore,” for the full story: https://lnkd.in/gmshyzFj Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are open. Secure your spot today to join us at LSI Asia ‘25 on June 10th-13th at The Ritz-Carlton, Millenia Singapore.

The ABCs of LSI USA are back! Today our letter of the day is A for Artificial Intelligence (AI). Throughout the event, we had multiple sessions that dove into various topics and impacts of AI including: Signature Series: No Corporate Slides. Real Strategies and Resources to Deliver Purpose-Driven AI ? Armen Vidian — Founder & Managing Partner, Recode Ventures ? Anne Osdoit — CEO, Moon Surgical ? Gabriel Jones — Founder & CEO, Proprio Panel: The AI Business-Building Era — Unlocking New Levels of Speed in Product Development, GTM, and More ? Robert Fenton — Founder & CEO, Qualio ? ?? Jim Schwoebel — Co-Founder & CEO of Quome ? Rachna Dayal — Founder & Managing Partner, Sugati Ventures Panel: How Will AI Revolutionize Imaging and Cardiovascular Care? ? Armen Vidian — Founder & Managing Partner, Recode Ventures ? Jyoti Gera — CEO, Cardiovascular and Interventional Solutions, GE HealthCare ? Adrian Lam, CFA — CEO, CorVista? Health ? Daniel Hawkins — CEO, Vista.ai Workshop: AI Agents and Models — Today, and Tomorrow ? Amrit Panjabi — Digital Health, AI, and Healthcare Analyst, CB Insights ? Vishal Gulati — Founder and Managing Partner, Recode Ventures The video recordings of these sessions will be available in the coming weeks. Tune in each day as we recap LSI USA ‘25 from A to Z. PS: Registration is now open for LSI USA ‘26 next March 16-20 in Dana Point, California. Secure your spot early to take advantage of our best rates and have first priority for our hotel room block.

Calla Lily Clinical Care (LSI Asia '25 Presenter) is a women's health-focused company that has developed the proprietary Callavid? platform for intravaginal drug delivery. Initial target indications are in IVF and miscarriage prevention, followed by delivery of live biotherapeutics (LBPs) to reduce antibiotic usage which contributes to antimicrobial resistance (AMR). Further use-cases include effective sample collection to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions. Join us in welcoming Co-Founder & CEO, Thang Vo-Ta?to LSI Asia ’25, where he’ll be presenting the company’s latest updates. Want to join us at LSI Asia ‘25 this June 10-13 in Singapore? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are open. Secure your spot today on our website.

Following the momentum of LSI USA ’25, we're gearing up for the next two stops on the global stage: LSI Asia ’25 in Singapore this June, followed by LSI Europe ’25 in London this September. ???? 11 Weeks Until LSI Asia ’25 in Singapore We’re thrilled to host our inaugural LSI Asia ’25 event in Singapore. With new partnerships spanning Singapore, China, Korea, Japan, and more, LSI Asia '25 will convene world-class startups, venture capital and private equity investors, strategics, and more. View the preliminary agenda and growing list of innovators, investors, and strategics set to join us in Singapore on our website. ???? 23 Weeks Until LSI Europe ’25 in London Now in its fourth year, LSI Europe has become a cornerstone for the global Medtech and Healthtech community. Our 2025 event will be held at the JW Marriott Grosvenor House in London from September 7th to 11th. You can look forward to the industry’s most innovative startups, venture capital, and private equity investors, strategics, and more gathered in one place. Want to get involved in LSI Asia ‘25 or LSI Europe ‘25? Submit your application to present, exhibit, and attend the event on our website today.

Powerful Medical (#LSIAlumni) received FDA Breakthrough Designation for its PMcardio STEMI AI ECG Model. This designation recognizes PMcardio as a breakthrough technology for the detection of ST-elevation myocardial infarction (STEMI) and STEMI equivalents—a life-threatening cardiac condition requiring immediate intervention. PMcardio is the only AI capable of detecting heart attacks on ECGs, significantly outperforming human physicians and existing tests. Already CE-certified under EU MDR, it tackles a global challenge: heart attacks remain the leading cause of death worldwide, with 12 million fatalities annually—and up to 50% are initially misdiagnosed, delaying care and increasing mortality. Powerful Medical’s solution aims to reduce STEMI-related mortality by 75% over the next five years, while also delivering major financial value to hospitals through improved triage, fewer false positives, and faster bed turnover. Congratulations to LSI Alumni Martin Herman, Timea Kisova, Felix Bauer, and the entire Powerful Medical team on this major milestone!

With LSI USA ‘25 in the rearview, our focus shifts to LSI Asia ‘25 where we recently unveiled our first batch of presenting companies selected to present this June 10-13 in Singapore. With our exciting new partnerships in Singapore, China, Korea, Japan, and more, LSI Asia will convene world-class startups, venture capital and private equity investors, strategics, and more. Here’s a sneak peak: ? Dr Lynne Lim — Nousq Pte Ltd ? Alex Jiao — Scout ? Bora Chang, MD — KēlaHealth ? Yossi Bar — LEM Surgical AG ? Shieak Tzeng — Wellumio ? Christopher Haig — Efemoral Medical ? Caitlin Morse — BrainSpace ? Malcolm Hebblewhite — Atmo Biosciences ? Lloyd Mencinger — AQUA Medical Interested in joining them? Apply to present today for your opportunity to connect with the APAC's top decision-makers at LSI Asia '25 on June 10-13 in Singapore. We’ll get back to you within 48 hours:?https://lnkd.in/g77Am_Td